Jul 14, 2021 / 05:30PM GMT
Matthew Kaplan - Ladenburg Thalmann & Co. Inc. - Analyst
It's my pleasure to introduce our next presenting company, Tarsus. Presenting for the Company today will be the CEO, Bobby Azamian. Bobby, thank you for taking part in our conference today. And I'm going to hand the podium over to you and give you a chance to present the Company, and then hopefully, we will have time for questions after your introduction.
Bobby Azamian - Tarsus Pharmaceuticals, Inc. - President and CEO
Thank you, Matt. Really a pleasure to be with you here today. And I'm excited to introduce the audience -- or update the audience, depending on the investors listening to Tarsus, in what we're up to. So I will be making forward-looking statements.
And I wanted to start with our vision and mission. So from day 1, we've been focused on really charting new ground and developing a brand-new drug for a brand-new indication. That's TP-03 for Demodex blepharitis. And I started the Company with that mission, to not only deliver a really important new therapy but also a scalable company
Tarsus Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers